Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Future Physicians Develop Conflict Of Interest Curriculum For Nation's Academic Medical Centers
- Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused By Diabetic Neuropathy
- Cyberonics Provides Update On Depression Post-Approval Study
- Democrats Push Medical Device Liability Bill
- Stem Cell Therapeutics Corp. Announces Positive Review By Data Safety And Monitoring Board For The Phase IIb Stroke Trial
- Risk Of HIV Transmission Not Reduced By Herpes Medication
- Endocyte Announces Positive Results From A Phase II Clinical Study Of EC145 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- World's Largest Malaria Vaccine Trial Now Underway In 7 African Countries
- Survey: 40 Percent Of Senior Citizens Not Taking Prescribed Medicines Due To Budget Concerns
- Diabetes Experts Underline Benefits Of SMBG For All Types Of Treatment Plans
Medivation Selects ProTrials To Conduct International Phase III Clinical Trials
Posted by: admin in Pharmacy Drugs on June 02nd, 2009
ProTrials Research, Inc.TM, a leader in the clinical research organization industry, announced Medivation, Inc. (NASDAQ:MDVN) has chosen the company to conduct separate international Phase III clinical trials for two novel treatments. ProTrials will test MDV3100 for treating prostate cancer and the investigational drug Dimebon TM as a treatment for Huntington’s disease. Due to the complex nature of these Phase III trials, Medivation again selected ProTrials as its contract research organization partner because of ProTrials’ successful past performance with the company’s Phase I, II and III trials.
“We are working with ProTrials specifically because of its people and their long track records of conducting clinical trials,” noted Lynn Seely, M.D., chief medical officer at Medivation. “While many CROs have research managers that are industry veterans, it’s unusual to find a CRO offering such deep experience levels across the team.”
ProTrials will oversee the Huntington’s trial across the United States, Canada and Europe, and the United States and Canada for the prostate cancer trial. Both clinical trials are expansive in nature, involving hundreds of patients and about 125 test sites total. They will both be randomized and placebo-controlled.
“Medivation’s repeated selection of ProTrials as a clinical trials partner is a nod to our track record of efficiency, cost effectiveness and most importantly, our GCP compliance in conducting clinical trials,” said ProTrials CEO Jodi Andrews. “With prostate cancer being one of the most prevalent types of cancer in men, and Huntington’s disease having no treatments currently approved by the U.S. Food and Drug Administration , these Phase III clinical trials are crucial for moving potentially life-saving treatments to market.”
Visitors to the upcoming 2009 American Society for Clinical Oncology (ASCO), being held May 29-June 2 at the Orange County Convention Center in Orlando, FL, can learn more about ProTrials in booth #703. ProTrials will also be attending the 45th Annual Meeting of the Drug Information Association (DIA), being held June 21-25 at the San Diego (CA) Convention Center, and will be in booth #1215.
Source
ProTrials Research, Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.